1e2k
From Proteopedia
| Line 4: | Line 4: | ||
|PDB= 1e2k |SIZE=350|CAPTION= <scene name='initialview01'>1e2k</scene>, resolution 1.7Å | |PDB= 1e2k |SIZE=350|CAPTION= <scene name='initialview01'>1e2k</scene>, resolution 1.7Å | ||
|SITE= <scene name='pdbsite=AC1:Tmc+Binding+Site+For+Chain+A'>AC1</scene> and <scene name='pdbsite=AC2:Tmc+Binding+Site+For+Chain+B+Symmetry+Related+Subunits+C+...'>AC2</scene> | |SITE= <scene name='pdbsite=AC1:Tmc+Binding+Site+For+Chain+A'>AC1</scene> and <scene name='pdbsite=AC2:Tmc+Binding+Site+For+Chain+B+Symmetry+Related+Subunits+C+...'>AC2</scene> | ||
| - | |LIGAND= <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene> | + | |LIGAND= <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene>, <scene name='pdbligand=TMC:1-[4-HYDROXY-5-(HYDROXYMETHYL)BICYCLO[3.1.0]HEX-2-YL]-5-METHYLPYRIMIDINE-2,4(1H,3H)-DIONE'>TMC</scene> |
| - | |ACTIVITY= [http://en.wikipedia.org/wiki/Thymidine_kinase Thymidine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.1.21 2.7.1.21] | + | |ACTIVITY= <span class='plainlinks'>[http://en.wikipedia.org/wiki/Thymidine_kinase Thymidine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.1.21 2.7.1.21] </span> |
|GENE= | |GENE= | ||
| + | |DOMAIN= | ||
| + | |RELATEDENTRY= | ||
| + | |RESOURCES=<span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1e2k FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1e2k OCA], [http://www.ebi.ac.uk/pdbsum/1e2k PDBsum], [http://www.rcsb.org/pdb/explore.do?structureId=1e2k RCSB]</span> | ||
}} | }} | ||
| Line 16: | Line 19: | ||
==About this Structure== | ==About this Structure== | ||
| - | 1E2K is a [[Single protein]] structure of sequence from [http://en.wikipedia.org/wiki/ | + | 1E2K is a [[Single protein]] structure of sequence from [http://en.wikipedia.org/wiki/Human_herpesvirus_1 Human herpesvirus 1]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1E2K OCA]. |
==Reference== | ==Reference== | ||
Kinetics and crystal structure of the wild-type and the engineered Y101F mutant of Herpes simplex virus type 1 thymidine kinase interacting with (North)-methanocarba-thymidine., Prota A, Vogt J, Pilger B, Perozzo R, Wurth C, Marquez VE, Russ P, Schulz GE, Folkers G, Scapozza L, Biochemistry. 2000 Aug 8;39(31):9597-603. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/10924157 10924157] | Kinetics and crystal structure of the wild-type and the engineered Y101F mutant of Herpes simplex virus type 1 thymidine kinase interacting with (North)-methanocarba-thymidine., Prota A, Vogt J, Pilger B, Perozzo R, Wurth C, Marquez VE, Russ P, Schulz GE, Folkers G, Scapozza L, Biochemistry. 2000 Aug 8;39(31):9597-603. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/10924157 10924157] | ||
| - | [[Category: Human herpesvirus | + | [[Category: Human herpesvirus 1]] |
[[Category: Single protein]] | [[Category: Single protein]] | ||
[[Category: Thymidine kinase]] | [[Category: Thymidine kinase]] | ||
| Line 26: | Line 29: | ||
[[Category: Schulz, G E.]] | [[Category: Schulz, G E.]] | ||
[[Category: Vogt, J.]] | [[Category: Vogt, J.]] | ||
| - | [[Category: SO4]] | ||
| - | [[Category: TMC]] | ||
[[Category: antiviral drug]] | [[Category: antiviral drug]] | ||
[[Category: enzyme-prodrug gene therapy]] | [[Category: enzyme-prodrug gene therapy]] | ||
| Line 34: | Line 35: | ||
[[Category: x-ray structure]] | [[Category: x-ray structure]] | ||
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun Mar 30 19:53:42 2008'' |
Revision as of 16:53, 30 March 2008
| |||||||
| , resolution 1.7Å | |||||||
|---|---|---|---|---|---|---|---|
| Sites: | and | ||||||
| Ligands: | , | ||||||
| Activity: | Thymidine kinase, with EC number 2.7.1.21 | ||||||
| Resources: | FirstGlance, OCA, PDBsum, RCSB | ||||||
| Coordinates: | save as pdb, mmCIF, xml | ||||||
KINETICS AND CRYSTAL STRUCTURE OF THE WILD-TYPE AND THE ENGINEERED Y101F MUTANT OF HERPES SIMPLEX VIRUS TYPE 1 THYMIDINE KINASE INTERACTING WITH (NORTH)-METHANOCARBA-THYMIDINE
Overview
Kinetic and crystallographic analyses of wild-type Herpes simplex virus type 1 thymidine kinase (TK(HSV1)) and its Y101F-mutant [TK(HSV1)(Y101F)] acting on the potent antiviral drug 2'-exo-methanocarba-thymidine (MCT) have been performed. The kinetic study reveals a 12-fold K(M) increase for thymidine processed with Y101F as compared to the wild-type TK(HSV1). Furthermore, MCT is a substrate for both wild-type and mutant TK(HSV1). Its binding affinity for TK(HSV1) and TK(HSV1)(Y101F), expressed as K(i), is 11 microM and 51 microM, respectively, whereas the K(i) for human cytosolic thymidine kinase is as high as 1.6 mM, rendering TK(HSV1) a selectivity filter for antiviral activity. Moreover, TK(HSV1)(Y101F) shows a decrease in the quotient of the catalytic efficiency (k(cat)/K(M)) of dT over MCT corresponding to an increased specificity for MCT when compared to the wild-type enzyme. Crystal structures of wild-type and mutant TK(HSV1) in complex with MCT have been determined to resolutions of 1.7 and 2.4 A, respectively. The thymine moiety of MCT binds like the base of dT while the conformationally restricted bicyclo[3.1.0]hexane, mimicking the sugar moiety, assumes a 2'-exo envelope conformation that is flatter than the one observed for the free compound. The hydrogen bond pattern around the sugar-like moiety differs from that of thymidine, revealing the importance of the rigid conformation of MCT with respect to hydrogen bonds. These findings make MCT a lead compound in the design of resistance-repellent drugs for antiviral therapy, and mutant Y101F, in combination with MCT, opens new possibilities for gene therapy.
About this Structure
1E2K is a Single protein structure of sequence from Human herpesvirus 1. Full crystallographic information is available from OCA.
Reference
Kinetics and crystal structure of the wild-type and the engineered Y101F mutant of Herpes simplex virus type 1 thymidine kinase interacting with (North)-methanocarba-thymidine., Prota A, Vogt J, Pilger B, Perozzo R, Wurth C, Marquez VE, Russ P, Schulz GE, Folkers G, Scapozza L, Biochemistry. 2000 Aug 8;39(31):9597-603. PMID:10924157
Page seeded by OCA on Sun Mar 30 19:53:42 2008
